Danaher (NYSE:DHR) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Danaher (NYSE:DHR) released its earnings results on Monday. The conglomerate reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12, FiscalAI reports. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion.

Danaher Stock Performance

NYSE DHR opened at $195.79 on Tuesday. The firm has a market capitalization of $138.56 billion, a P/E ratio of 38.85, a P/E/G ratio of 2.64 and a beta of 0.95. Danaher has a 1-year low of $180.03 and a 1-year high of $242.80. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. The business’s 50-day simple moving average is $198.39 and its 200-day simple moving average is $214.70.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. This is an increase from Danaher’s previous quarterly dividend of $0.32. Danaher’s dividend payout ratio is presently 31.75%.

Analyst Ratings Changes

A number of equities research analysts have commented on DHR shares. Rothschild & Co Redburn set a $205.00 target price on Danaher in a report on Friday. Evercore reduced their target price on Danaher from $254.00 to $225.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Leerink Partners raised their target price on Danaher from $260.00 to $270.00 and gave the company an “outperform” rating in a report on Friday, January 16th. Barclays dropped their price objective on Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Finally, TD Cowen dropped their price objective on Danaher from $270.00 to $245.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Eighteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $246.50.

Insider Buying and Selling at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. The trade was a 20.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 10.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Danaher

Several hedge funds and other institutional investors have recently modified their holdings of DHR. Sivia Capital Partners LLC lifted its stake in shares of Danaher by 6.3% in the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after purchasing an additional 119 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of Danaher by 34.5% in the 2nd quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after purchasing an additional 14,217 shares in the last quarter. Main Street Financial Solutions LLC lifted its stake in shares of Danaher by 40.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock valued at $610,000 after purchasing an additional 886 shares in the last quarter. Ieq Capital LLC lifted its stake in shares of Danaher by 64.2% in the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock valued at $14,957,000 after purchasing an additional 29,592 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its stake in shares of Danaher by 30.7% in the 2nd quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock valued at $273,000 after purchasing an additional 325 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat — Danaher reported $2.06 EPS vs. consensus ~ $1.94–1.95, showing year?over?year improvement and better profitability that beat expectations. Danaher (DHR) Q1 Earnings Beat Estimates
• Positive Sentiment: Guidance lifted — Management raised the upper end of FY?2026 EPS guidance to a range of 8.350–8.550, signaling confidence in ongoing strength in biotech and life?sciences end markets. That upward guidance is supportive for forward earnings expectations. Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
• Positive Sentiment: Bioprocessing demand driving results — Management and reporters cited double?digit momentum in the Biotechnology & Life Sciences segment and strong demand for bioprocessing tools used in drug manufacturing, a durable end?market that lifted shares in premarket trading. Danaher beats first-quarter profit estimates on strong bioprocessing demand
• Neutral Sentiment: Revenue slightly below estimates — Revenue came in at $5.95B vs. consensus ~$6.0B, a modest miss that tempers the beat and will be watched for signs of order patterns across segments. Management materials and the slide deck provide additional detail on segment trends. Danaher Reports First Quarter 2026 Results (Press Release / Slide Deck)

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.